13D Filings
INTEGRATED BIOPHARMA INC
INBP
Initial Filing
Ownership

41.30%

Total Shares

12,920,558

Issuer CIK

1016504

Event Date

Apr 14, 2026

Accepted

Apr 17, 2026, 03:48 PM

Reporting Persons (2)
NameType% of ClassAggregateSole VotingShared Voting
DeSantis Damon
Individual
41.30%12,920,558187,50012,733,058
CDDS 2.0, LLC
Other
41.00%12,733,05812,733,0580
Disclosure Items (7)

Security Title

Common Stock

Issuer Name

INTEGRATED BIOPHARMA INC

Issuer Address

225 LONG AVENUE, HILLSIDE, NJ, 07205

Filing Persons

(i) CDDS 2.0, LLC, a Florida limited liability company ('CDDS') (ii) Damon DeSantis, an individual ('DeSantis', and, together with CDDS, the 'Group')

Business Address

(i) CDDS: 109 SE 5th Avenue Second Floor, Delray Beach, FL 33483 (ii) DeSantis: 109 SE 5th Avenue Second Floor, Delray Beach, FL 33483

Principal Occupation

(i) CDDS: N/A (ii) DeSantis: Retired

Convictions

N/A

Citizenship

(i) CDDS is a limited liability company organized under the laws of the State of Florida. (ii) DeSantis is a citizen of the United States.

The shares of Common Stock reported herein were acquired in the following three-step sequence for no cash consideration: (a) On March 24, 2026, March 30, 2026 and April 15, 2026, 1,356,293, 150,000 and 8,966,547 shares of Common Stock, respectively were transferred from CD Financial, LLC, a Florida limited liability company, to CDDS; (b) On March 24, 2026 and April 15, 2026, 7,392 and 2,235,417 shares of Common Stock, respectively, were transferred from the Carl DeSantis Revocable Trust to CDDS; and (c) On March 30, 2026, 17,409 shares of Common Stock were transferred from the Estate of Carl DeSantis to CDDS. DeSantis controls CDDS as its sole member. No funds or other consideration was used by either member of the Group to acquire the shares of Common Stock subject hereof, and no funds or other consideration were borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the shares of Common Stock subject hereof.

No member of the Group has a present intention or plans or proposals which relate to or could result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D. Notwithstanding anything to the contrary contained herein, each member of the Group reserves the right, depending on all relevant factors, to change their intentions with respect to any and all of the matters referred to above.

Percentage of Class

After giving effect to the transfers described in Item 3: (i) CDDS is the record and beneficial owner of 12,733,058 shares of Common Stock, representing approximately 41.0% of the outstanding shares of Common Stock (based on 31,059,610 shares of Common Stock outstanding as of April 15, 2026). (ii) DeSantis is the beneficial owner of an aggregate of 12,920,558 shares of Common Stock, representing approximately 41.3% of the outstanding shares of Common Stock (based on 31,059,610 shares of Common Stock outstanding as of April 15, 2026). DeSantis does not directly hold the shares of Common Stock described in the transfers set forth in Item 3. DeSantis directly holds 187,500 shares of Common Stock in the form of presently exercisable stock options.

Number of Shares

(i) CDDS has sole voting power and sole dispositive power with respect to the 12,733,058 shares of Common Stock. (ii) Through control of CDDS, DeSantis has shared voting power and shared dispositive power with respect to the 12,733,058 shares of Common Stock described in Item 3. DeSantis has sole voting power and sole dispositive power with respect to the 187,500 shares of Common Stock beneficially owned by DeSantis.

Transactions

Except for the transactions described in Item 3, neither member of the Group has effected any transaction in the shares of Common Stock subject hereof during the sixty (60) days prior to the date of this Statement.

Shareholders

Not applicable.

Date of 5% Ownership

Not applicable.

Neither member of the Group has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer of voting of securities, finder's fees, joint venture, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses or the giving or withholding of proxies, other than stock options issued by the Issuer to DeSantis.

99.1 Joint Filing Agreement, as required by Rule 13d-1 (k) under the Securities Exchange Act of 1934, as amended.

INTEGRATED BIOPHARMA INC — Schedule 13D | 13D Filings